摘要
树突状细胞（dendritic cell,DC）于1973年被发现,在抗肿瘤免疫治疗中的应用始于上个世纪80年代。从前体细胞产生DC制造了足够数量的抗原呈递细胞的方法,快速用于临床,从而产生了首个基于DC的疫苗接种研究。一般来说,这种形式的免疫治疗需要离体产生的DC负载肿瘤抗原,随后重新注射入患者,以刺激由CD8~＋和CD4~＋T淋巴细胞介导的抗肿瘤免疫应答。
Dendritic cells（DCs）are professional antigen-presenting cells which play a key role in both immunity induction and tolerance maintenance.DC is the strongest and the only one antigen presenting cell which can directly activate the initial T cells in vivo,initiating the adaptive immune response.In this paper,we discuss the new understanding of DC-based tumor immunotherapy,and the clinical studies of DCs that have been carried out so far in combination with other therapies.
出处
《临床血液学杂志》
CAS
2018年第1期62-65,共4页
Journal of Clinical Hematology
基金
安徽省自然科学基金项目(No:1508085MH195)
